Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 yearCitation formats

  • External authors:
  • Phoebe Rich
  • Kristian Reich
  • Frank O. Nestle
  • Richard K. Scher
  • Shu Li
  • Stephen Xu
  • Ming Chun Hsu
  • Cynthia Guzzo

Standard

Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. / Rich, Phoebe; Griffiths, Christopher E M; Reich, Kristian; Nestle, Frank O.; Scher, Richard K.; Li, Shu; Xu, Stephen; Hsu, Ming Chun; Guzzo, Cynthia.

In: Journal of the American Academy of Dermatology, Vol. 58, No. 2, 02.2008, p. 224-231.

Research output: Contribution to journalArticle

Harvard

Rich, P, Griffiths, CEM, Reich, K, Nestle, FO, Scher, RK, Li, S, Xu, S, Hsu, MC & Guzzo, C 2008, 'Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year', Journal of the American Academy of Dermatology, vol. 58, no. 2, pp. 224-231. https://doi.org/10.1016/j.jaad.2007.07.042

APA

Rich, P., Griffiths, C. E. M., Reich, K., Nestle, F. O., Scher, R. K., Li, S., ... Guzzo, C. (2008). Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. Journal of the American Academy of Dermatology, 58(2), 224-231. https://doi.org/10.1016/j.jaad.2007.07.042

Vancouver

Rich P, Griffiths CEM, Reich K, Nestle FO, Scher RK, Li S et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. Journal of the American Academy of Dermatology. 2008 Feb;58(2):224-231. https://doi.org/10.1016/j.jaad.2007.07.042

Author

Rich, Phoebe ; Griffiths, Christopher E M ; Reich, Kristian ; Nestle, Frank O. ; Scher, Richard K. ; Li, Shu ; Xu, Stephen ; Hsu, Ming Chun ; Guzzo, Cynthia. / Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. In: Journal of the American Academy of Dermatology. 2008 ; Vol. 58, No. 2. pp. 224-231.

Bibtex

@article{6380b1a06713420796e469e23fc39f8a,
title = "Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year",
abstract = "Background: Although nail psoriasis occurs frequently in patients with psoriatic skin lesions, effective treatments are limited. Objective: Occurrence of nail psoriasis by type and incidence of nail clearance using the Nail Psoriasis Severity Index were evaluated. Methods: This was a 50-week, phase III study in which 378 patients with moderate to severe psoriasis were randomized 4:1 to infliximab (5 mg/kg) or placebo at weeks 0, 2, 6, and every 8 weeks through week 46, with placebo crossover to infliximab at week 24. Results: Of the 373 evaluated patients, 305 (81.8{\%}) had baseline nail psoriasis. The right thumbnail was most often the worst involved nail, and pitting and onycholysis were the most common lesions. Among patients with baseline nail psoriasis, 6.9{\%}, 26.2{\%}, and 44.7{\%} in the infliximab group had nail disease clearance at weeks 10, 24, and 50, respectively, versus 5.1{\%} in the placebo group at week 24 (P <.001). Mean percent improvements in Nail Psoriasis Severity Index score at weeks 10 and 24 were 26.8{\%} and 57.2{\%}, respectively, in the infliximab group versus -7.7{\%} and -4.1{\%}, respectively, in the placebo group (both P <.001). At week 24, mean percent improvements in nail matrix and nail bed features were 52.9{\%} and 69.2{\%}, respectively (vs -1.9{\%} and 18.4{\%} for placebo; P <.001). Limitations: The study did not evaluate nail response beyond 1 year. Conclusions: Patients with psoriasis receiving infliximab experienced marked and sustained nail improvement. {\circledC} 2008 American Academy of Dermatology, Inc.",
keywords = "Adult, therapeutic use: Antibodies, Monoclonal, Female, Humans, Male, Middle Aged, drug therapy: Nail Diseases, drug therapy: Psoriasis",
author = "Phoebe Rich and Griffiths, {Christopher E M} and Kristian Reich and Nestle, {Frank O.} and Scher, {Richard K.} and Shu Li and Stephen Xu and Hsu, {Ming Chun} and Cynthia Guzzo",
year = "2008",
month = "2",
doi = "10.1016/j.jaad.2007.07.042",
language = "English",
volume = "58",
pages = "224--231",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby, Inc.",
number = "2",

}

RIS

TY - JOUR

T1 - Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year

AU - Rich, Phoebe

AU - Griffiths, Christopher E M

AU - Reich, Kristian

AU - Nestle, Frank O.

AU - Scher, Richard K.

AU - Li, Shu

AU - Xu, Stephen

AU - Hsu, Ming Chun

AU - Guzzo, Cynthia

PY - 2008/2

Y1 - 2008/2

N2 - Background: Although nail psoriasis occurs frequently in patients with psoriatic skin lesions, effective treatments are limited. Objective: Occurrence of nail psoriasis by type and incidence of nail clearance using the Nail Psoriasis Severity Index were evaluated. Methods: This was a 50-week, phase III study in which 378 patients with moderate to severe psoriasis were randomized 4:1 to infliximab (5 mg/kg) or placebo at weeks 0, 2, 6, and every 8 weeks through week 46, with placebo crossover to infliximab at week 24. Results: Of the 373 evaluated patients, 305 (81.8%) had baseline nail psoriasis. The right thumbnail was most often the worst involved nail, and pitting and onycholysis were the most common lesions. Among patients with baseline nail psoriasis, 6.9%, 26.2%, and 44.7% in the infliximab group had nail disease clearance at weeks 10, 24, and 50, respectively, versus 5.1% in the placebo group at week 24 (P <.001). Mean percent improvements in Nail Psoriasis Severity Index score at weeks 10 and 24 were 26.8% and 57.2%, respectively, in the infliximab group versus -7.7% and -4.1%, respectively, in the placebo group (both P <.001). At week 24, mean percent improvements in nail matrix and nail bed features were 52.9% and 69.2%, respectively (vs -1.9% and 18.4% for placebo; P <.001). Limitations: The study did not evaluate nail response beyond 1 year. Conclusions: Patients with psoriasis receiving infliximab experienced marked and sustained nail improvement. © 2008 American Academy of Dermatology, Inc.

AB - Background: Although nail psoriasis occurs frequently in patients with psoriatic skin lesions, effective treatments are limited. Objective: Occurrence of nail psoriasis by type and incidence of nail clearance using the Nail Psoriasis Severity Index were evaluated. Methods: This was a 50-week, phase III study in which 378 patients with moderate to severe psoriasis were randomized 4:1 to infliximab (5 mg/kg) or placebo at weeks 0, 2, 6, and every 8 weeks through week 46, with placebo crossover to infliximab at week 24. Results: Of the 373 evaluated patients, 305 (81.8%) had baseline nail psoriasis. The right thumbnail was most often the worst involved nail, and pitting and onycholysis were the most common lesions. Among patients with baseline nail psoriasis, 6.9%, 26.2%, and 44.7% in the infliximab group had nail disease clearance at weeks 10, 24, and 50, respectively, versus 5.1% in the placebo group at week 24 (P <.001). Mean percent improvements in Nail Psoriasis Severity Index score at weeks 10 and 24 were 26.8% and 57.2%, respectively, in the infliximab group versus -7.7% and -4.1%, respectively, in the placebo group (both P <.001). At week 24, mean percent improvements in nail matrix and nail bed features were 52.9% and 69.2%, respectively (vs -1.9% and 18.4% for placebo; P <.001). Limitations: The study did not evaluate nail response beyond 1 year. Conclusions: Patients with psoriasis receiving infliximab experienced marked and sustained nail improvement. © 2008 American Academy of Dermatology, Inc.

KW - Adult

KW - therapeutic use: Antibodies, Monoclonal

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - drug therapy: Nail Diseases

KW - drug therapy: Psoriasis

U2 - 10.1016/j.jaad.2007.07.042

DO - 10.1016/j.jaad.2007.07.042

M3 - Article

VL - 58

SP - 224

EP - 231

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 2

ER -